This story originally ran on Feb. 2.
Strategic Diagnostics this week announced that Science Applications International Corp.-Frederick has chosen it to develop monoclonal antibodies as part of the National Cancer Institute's initiative to improve reagents for the proteomics community.
GenomeWeb Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives
Never miss another important industry story.
Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.
*Before your trial expires, we’ll put together a custom quote with your long-term premium options.
